Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800
Debt
Debt-to-Equity Ratio-3.11
Current Ratio2.11
Quick Ratio1.59
Price-To-Earnings
Trailing P/E Ratio-3.53
Forward P/E Ratio-4.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$24.73 million
Price / Sales15.56
Cash FlowN/A
Price / CashN/A
Book Value($0.32) per share
Price / Book-22.22
Profitability
EPS (Most Recent Fiscal Year)($2.02)
Net Income$-82,330,000.00
Net Margins-338.43%
Return on EquityN/A
Return on Assets-67.83%
Miscellaneous
Employees407
Outstanding Shares54,120,000
Market Cap$417.28 million
Quotient (NASDAQ:QTNT) Frequently Asked Questions
What is Quotient's stock symbol?
Quotient trades on the NASDAQ under the ticker symbol "QTNT."
How were Quotient's earnings last quarter?
Quotient Ltd (NASDAQ:QTNT) issued its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.18. The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $6.90 million. View Quotient's Earnings History.
When is Quotient's next earnings date?
What price target have analysts set for QTNT?
2 analysts have issued 1-year price objectives for Quotient's stock. Their forecasts range from $10.00 to $13.00. On average, they anticipate Quotient's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 61.5% from the stock's current price. View Analyst Price Targets for Quotient.
What is the consensus analysts' recommendation for Quotient?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.
What are Wall Street analysts saying about Quotient stock?
Here are some recent quotes from research analysts about Quotient stock:
- 1. According to Zacks Investment Research, "Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. " (6/2/2018)
- 2. BTIG Research analysts commented, "PT: QTNT reported F4Q18 (March) results, with the legacy conventional reagent business continuing to post solid growth (+19% for FY18). More importantly, the company announced the appointment of Mr. Franz Walt as the CEO (previously Interim CEO; see our note here), who we believe has the track record of strong leadership in the diagnostics industry to lead QTNT through MosaiQ commercialization and the next phase of growth. The European field trials for the initial MosaiQ IH microarray are well underway, and based on early observations, QTNT remains confident in completing the concordance phase of the trials in June and European regulatory submission in the second half of CY18. Beyond the initial IH microarray, QTNT is targeting European regulatory submission for the initial serological disease screening (SDS) microarray in the first half of CY19, commencement of U.S." (5/30/2018)
Who are some of Quotient's key competitors?
Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF) and Fluoropharma Medical (FPMI).
Who are Quotient's key executives?
Quotient's management team includes the folowing people:
- Mr. Jeremy Stackawitz, Pres (Age 43)
- Mr. Edward Farrell, Pres (Age 48)
- Mr. Christopher J. Lindop, Chief Financial Officer (Age 60)
- Mr. Franz Walt, CEO & Director (Age 58)
- Mr. John Allan, Corp. Sr. VP & CTO
Has Quotient been receiving favorable news coverage?
News coverage about QTNT stock has been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quotient earned a daily sentiment score of 0.04 on Accern's scale. They also gave news articles about the company an impact score of 44.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Quotient.
Who are Quotient's major shareholders?
Quotient's stock is owned by many different of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.85%), Point72 Asset Management L.P. (0.73%), Bellevue Group AG (0.64%), Gilder Gagnon Howe & Co. LLC (0.42%), Paloma Partners Management Co (0.29%) and Citadel Advisors LLC (0.21%). Company insiders that own Quotient stock include Brian Mcdonough, D J Paul E Cowan, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Institutional Ownership Trends for Quotient.
Which major investors are buying Quotient stock?
QTNT stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Gilder Gagnon Howe & Co. LLC, Bellevue Group AG, Paloma Partners Management Co, Citadel Advisors LLC, FNY Investment Advisers LLC and LMR Partners LLP. Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.
How do I buy shares of Quotient?
Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quotient's stock price today?
One share of QTNT stock can currently be purchased for approximately $7.12.
How big of a company is Quotient?
Quotient has a market capitalization of $417.28 million and generates $24.73 million in revenue each year. The company earns $-82,330,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. Quotient employs 407 workers across the globe.
How can I contact Quotient?
Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.
MarketBeat Community Rating for Quotient (NASDAQ QTNT)
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
